Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00657020
First received: April 2, 2008
Last updated: February 12, 2015
Last verified: June 2013
  Purpose

A single center, double blind, randomized, placebo controlled, two-treatments, two-period crossover study conducted in adult smokers.


Condition Intervention Phase
Smoking
Drug: Nicotine
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Simultaneous fMRI/EEG of the 4 mg Nicotine Lozenge in Relief of Cognitive Impairment Associated With Nicotine Withdrawal

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Percent Mean Change in Blood Oxygen-level Dependent (BOLD) Scores During Rapid Visual Information Processing (RVIP) Task [ Time Frame: Approximately 2 hours post dose administration ] [ Designated as safety issue: No ]
    In RVIP task, participant responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. During a control task, participant responded to single occurrences of the number "0". BOLD fMRI signals evaluated different brain regions of interest (ROI) during RVIP task. Brain ROIs identified were right and left anterior insula, anterior putamen, parietal cortex, premotor cortex, visual cortex, dorsal anterior cingulate cortex, substantia nigra and thalamus.


Secondary Outcome Measures:
  • Mean Response Time for Correct Responses During RVIP Task [ Time Frame: Approximately 2 hours post dose administration ] [ Designated as safety issue: No ]
    During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. During a control task, participants responded to single occurrences of the number "0". Mean response time for correct responses was determined.

  • Mean Percentage of Correct Responses During RVIP Task [ Time Frame: Approximately 2 hours post dose administration ] [ Designated as safety issue: No ]
    Percentage of correct responses during RVIP task was determined

  • Percent Mean Change in BOLD Scores During Divided Attention (DIA) Task [ Time Frame: Approximately 2 hours post dose admininstration ] [ Designated as safety issue: No ]
    BOLD fMRI signals evaluated different brain ROIs during DIA task which comprised of three conditions: i) Sustained visual attention wherein participant responded to letter "s" every time it appeared in a continuous stream of letters on a screen; ii) Sustained auditory attention wherein participant responded to the number "8" each time in appeared in a continuous stream of numbers presented through headphones; iii) Divided attention task auditory and visual stimuli wherein participant responded to occurrences of "s" (visual) and "8" (auditory) simultaneously. Brain ROIs were right and left parietal cortex, visual cortex, superior occipital cortex and right premotor cortex.

  • Mean Response Time for Correct Responses During DIA Task [ Time Frame: Approximately 2 hours post dose administration ] [ Designated as safety issue: No ]
    DIA task comprised of three conditions: i) Sustained visual attention wherein participant responded to letter "s" every time it appeared in a continuous stream of letters on a screen; ii) Sustained auditory attention wherein participant responded to the number "8" each time in appeared in a continuous stream of numbers presented through headphones; iii) Divided attention task auditory and visual stimuli wherein participant responded to occurrences of "s" (visual) and "8" (auditory) simultaneously. Mean response time for correct responses was determined.

  • Mean Percentage of Correct Responses During DIA Task [ Time Frame: Approximately 2 hours post dose administration ] [ Designated as safety issue: No ]
    Mean percentage of correct responses during DIA task was determined.


Enrollment: 23
Study Start Date: September 2007
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nicotine lozenge
Nicotine lozenge containing 4 mg of nicotine to be placed in mouth and suck to dissolution.
Drug: Nicotine
Nicotine lozenge containing 4 mg of nicotine
Other Name: Nicotine
Placebo Comparator: Placebo lozenge
Placebo lozenge to be placed in mouth and suck to dissolution.
Drug: Placebo
Placebo lozenge

Detailed Description:

The main objective of this study is to use blood oxygen level-dependent (BOLD) functional Magnetic Resonance Imaging (fMRI) in abstinent smokers to directly evaluate the effect of the 4 milligrams (mg) nicotine lozenge on brain activation associated with visual attention. The experimental task featured 3 conditions: 1. a highly demanding cognitive/attention task, 2. a simple cognitive/attention task, and 3. simply look at a '+' symbol. During the experiment these conditions are each presented a number of times in an alternating manner while acquiring images.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Weight and size

    1. Body mass index (BMI) within the range 19.0-32.0 kg/m.
    2. Able to fit comfortably within the MR scanner.
  • Smoking Status

    1. Cigarette smokers that consume their first manufactured cigarette (i.e., not self rolled cigarettes) within 30 min of waking.
    2. Individuals who have smoked regularly for at least a year.
  • Females of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception.
  • Understands and is willing, able and likely to comply with all study procedures and restrictions.
  • Good general health with (in the opinion of the examining study doctor) no clinically significant and relevant abnormalities of medical history, physical examination or clinical laboratory test.
  • Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.

Exclusion Criteria:

  • Women who are pregnant or who have a positive urine pregnancy test or
  • who are breast-feeding.
  • Disease/Illness

    1. Any clinically significant medical history or abnormality found on physical examination, laboratory assessment or electrocardiogram (ECG) at screening which, in the opinion of the investigator, could interfere with the interpretation of efficacy or safety data or which otherwise would contraindicate participation in a clinical trial.
    2. Current or recent history or presence of a neurological diagnosis (not limited to but including for example, stroke, traumatic brain injury, carotid arterial sclerotic disease, epilepsy, space occupying lesions, multiple sclerosis, Parkinson's disease, vascular dementia, transient ischemic attack, schizophrenia, major depression etc.) that may influence the outcome or analysis of the scan results.
  • Contraindications to MR scanning

    1. Intracranial aneurysm clips
    2. History of intra-orbital metal fragments that have not been removed by a doctor (as confirmed by orbital X-Ray).
    3. Inner ear implants.
    4. Tattoos with metal containing inks or piercings that can not be removed except those, which, in the opinion of the Investigator, will not interfere with the study procedures or compromise safety.
    5. History of claustrophobia or subject feels unable to lie still on their back for a period of 90 min in the MR scanner.
    6. Presence of a cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a standard pre-MRI questionnaire supported by plain X-Rays where appropriate.
  • Prior/Concomitant Medication

    1. Use of any central nervous system (CNS) active, prescription medication within 14 days of first treatment visit.
    2. Use of any over the counter (OTC) medication within 14 days of each treatment visit except those, which, in the opinion of the Investigator, will not interfere with the study procedures or compromise safety. Paracetamol (up to 2 g) may be taken up to 24 hrs prior to each treatment visit.
    3. Current use of any nicotine replacement therapy.
  • Clinical Study/Experimental Medication

    1. Participation in another clinical study or receipt of an investigational drug within 3 months of the first treatment visit.
    2. Previous participation in this study.
  • Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
  • Substance abuse

    1. History of regular alcohol consumption exceeding an average weekly intake of more than 14 units per week for females, 21 units per week for males, or an average daily intake greater than 2 units for females and 3 units for males.
    2. Past history of drug abuse, excluding nicotine, or has tested positive for urine drugs of abuse at the screening or either treatment visit.
  • Consumption of any alcoholic beverages within 24 hours of the treatment visits (as indicated by either a positive breath alcohol test or in the opinion of the Investigator).
  • Consumption of large quantities of xanthine containing beverages (e.g., coffee, tea, cola, chocolate etc, more than an average of five cups or glasses per day).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00657020

Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00657020     History of Changes
Other Study ID Numbers: S3250493
Study First Received: April 2, 2008
Results First Received: October 12, 2009
Last Updated: February 12, 2015
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by GlaxoSmithKline:
nicotine
therapy
fMRI/EEG
replacement

Additional relevant MeSH terms:
Nicotine
Autonomic Agents
Cholinergic Agents
Cholinergic Agonists
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nicotinic Agonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on March 01, 2015